Replies to post #199414 on Biotech Values

[DewDiligence]

VICL -24% on failure of CMV vaccine in kidney-transplant patients:

http://finance.yahoo.com/news/vical-astellas-announce-topline-results-103000089.html

VICL seems to be one of those biotech companies that never gets anything right.